3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
7
Carboplatin
5
Cisplatin
4
Drug Therapy
3
Taxes
2
Specimen Handling
2
SS1(dsFv)PE38
2
Polymerase Chain Reaction
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Hyperthermic Intraperitoneal Chemotherapy
2
Gene Expression Profiling
2
Fluorouracil
2
Doxorubicin
2
Cyclophosphamide
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
tocilizumab
1
tinostamustine
1
sodium thiosulfate
1
selinexor
1
rucaparib
1
olaparib
1
motexafin lutetium
1
liposomal doxorubicin
1
fludarabine
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
tinostamustine
×
Thoracic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts